Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:13679474rdf:typepubmed:Citationlld:pubmed
pubmed-article:13679474lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C0268790lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C0663645lld:lifeskim
pubmed-article:13679474lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:13679474pubmed:issue10lld:pubmed
pubmed-article:13679474pubmed:dateCreated2003-9-18lld:pubmed
pubmed-article:13679474pubmed:abstractTextVasopeptidase inhibitors are a new class of compounds that inhibit both angiotensin-converting enzyme (ACE) and neutral endopeptidase. This study determined whether treatment with the vasopeptidase inhibitor omapatrilat (OMA) produced different effects on renal and cardiovascular structure compared with inhibition of ACE by enalapril (ENP) in rats with two-kidney, one clip hypertension (2K1C).lld:pubmed
pubmed-article:13679474pubmed:languageenglld:pubmed
pubmed-article:13679474pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:13679474pubmed:citationSubsetIMlld:pubmed
pubmed-article:13679474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:13679474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:13679474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:13679474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:13679474pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:13679474pubmed:statusMEDLINElld:pubmed
pubmed-article:13679474pubmed:monthOctlld:pubmed
pubmed-article:13679474pubmed:issn0931-0509lld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:WolfGunterGlld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:StahlRolf A...lld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:HelmchenUdoUlld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:AmannKerstinKlld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:WenzelUlrich...lld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:JacobIvonneIlld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:SchweglerChri...lld:pubmed
pubmed-article:13679474pubmed:authorpubmed-author:QasqasArishAlld:pubmed
pubmed-article:13679474pubmed:issnTypePrintlld:pubmed
pubmed-article:13679474pubmed:volume18lld:pubmed
pubmed-article:13679474pubmed:ownerNLMlld:pubmed
pubmed-article:13679474pubmed:authorsCompleteYlld:pubmed
pubmed-article:13679474pubmed:pagination2005-13lld:pubmed
pubmed-article:13679474pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:meshHeadingpubmed-meshheading:13679474...lld:pubmed
pubmed-article:13679474pubmed:year2003lld:pubmed
pubmed-article:13679474pubmed:articleTitleBeneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats.lld:pubmed
pubmed-article:13679474pubmed:affiliationUniversity Hospital of Hamburg-Eppendorf, Department of Medicine, Division of Nephrology, Pav. 61, Martinistrasse 52, D-20246 Hamburg, Germany. wenzel@uke.uni-hamburg.delld:pubmed
pubmed-article:13679474pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:13679474pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:13679474pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:13679474lld:pubmed